Mantle cell lymphoma (MCL) characteristically express CD20, CD5, and cyclin-D1, carries the translocation t(11;14) (q13;q32) and typically has no expression of germinal center cell markers. So-called aberrant phenotypes such as CD5 negative and cyclin-D1-negative MCL have been described. Also few cases with CD10 and/or BCL-6 protein expression have been reported. We analyzed 127 MCL looking for the frequency of aberrant immunophenotype, CD10, BCL-6, and MUM1 expression. All cases were CD20 and cyclin-D1 positive, 96% expressed CD5, and 98% showed the t(11;14). BCL-6 expression was observed in 12% of the cases and MUM1 in 35%. No one case showed CD10 positivity in 30% or more neoplastic cells. Only 3 cases showed 10% to 20% of tumoral cells positive for CD10. MUM1 expression was observed in 67% of the BCL-6 positive cases. Thirty-two percent of the cases showed a MUM1+/BCL-6-/CD10- phenotype and 56% had a triple-negative-pattern. Aberrant phenotype is infrequent but not rare, and does not rule out a diagnosis of MCL in an otherwise typical case.
Blood. 2003 May 15;101(10):4042-6
[PMID:
12511405]
Am J Hematol. 2000 Jul;64(3):190-6
[PMID:
10861815]
Blood. 2000 Apr 1;95(7):2253-61
[PMID:
10733493]
South Med J. 1998 Jun;91(6):584-7
[PMID:
9634125]
Mod Pathol. 2007 Jan;20(1):1-7
[PMID:
17057651]
Hum Pathol. 2002 Jan;33(1):7-20
[PMID:
11823969]
Histopathology. 2008 Jul;53(1):20-9
[PMID:
18518902]
Leukemia. 2000 Apr;14(4):563-6
[PMID:
10764139]
Am J Clin Pathol. 2002 Aug;118(2):216-24
[PMID:
12162681]
Hum Pathol. 2008 Jun;39(6):817-23
[PMID:
18436278]
Am J Clin Pathol. 2003 Feb;119(2):218-30
[PMID:
12579992]
Am J Clin Pathol. 2004 Jul;122(1):122-7
[PMID:
15272540]
Am J Surg Pathol. 1992 Jul;16(7):637-40
[PMID:
1530105]
Blood. 2004 Jan 1;103(1):275-82
[PMID:
14504078]
Nat Genet. 1997 Oct;17(2):226-30
[PMID:
9326949]
Blood. 2003 Jun 15;101(12):4975-81
[PMID:
12609845]
Haematologica. 2007 Feb;92(2):267-8
[PMID:
17296585]
Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312
[PMID:
9620643]
Blood. 1995 May 15;85(10):2877-84
[PMID:
7742550]
Blood. 2000 Mar 15;95(6):2084-92
[PMID:
10706878]
Hum Pathol. 2009 Apr;40(4):565-71
[PMID:
19144381]
Blood. 2003 Oct 15;102(8):3003-9
[PMID:
12842981]
Am J Surg Pathol. 2008 Aug;32(8):1190-200
[PMID:
18580679]
Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):109-12
[PMID:
18815567]
Am J Clin Pathol. 2002 Feb;117(2):291-300
[PMID:
11863226]
Mod Pathol. 2005 Mar;18(3):331-9
[PMID:
15257315]
Leuk Lymphoma. 2008 Feb;49(2):273-80
[PMID:
18231914]
Blood. 2000 Feb 15;95(4):1400-5
[PMID:
10666217]
Am J Surg Pathol. 2004 Aug;28(8):1051-6
[PMID:
15252312]
Leukemia. 2005 Aug;19(8):1471-8
[PMID:
15959530]
Hematology Am Soc Hematol Educ Program. 2007;:270-6
[PMID:
18024640]
Br J Haematol. 2000 Oct;111(1):247-57
[PMID:
11091208]
Blood. 2005 Dec 15;106(13):4315-21
[PMID:
16123218]
Leukemia. 2000 Mar;14(3):449-56
[PMID:
10720141]
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
CD5 Antigens
Cyclin D
DNA-Binding Proteins
Female
Gene Expression Regulation, Leukemic
Germinal Center
Humans
In Situ Hybridization, Fluorescence
Lymphoma, Mantle-Cell
Male
Middle Aged
Neprilysin
Oncogene Proteins, Fusion
Phenotype
Proto-Oncogene Proteins c-bcl-6
Retrospective Studies
Translocation, Genetic
BCL6 protein, human
Biomarkers, Tumor
CD5 Antigens
Cyclin D
DNA-Binding Proteins
IGH-CCND1 fusion protein, human
Oncogene Proteins, Fusion
Proto-Oncogene Proteins c-bcl-6
Neprilysin
